Objective: To study the expression and clinical significance of SATB1, BRMS1 in Ovarian serous adenocarcinoma.
Methods: Immanohistochemistrical SP method was used to detect the expression of SATB1, BRMS1 in 11 cases of normal ovarian tissue and 11 cases of benign ovarian tumor and 10 cases of ovarian borderline tumor and 53 cases ovarian serous adenocarcinoma.
Results: The expression of SATB1 in ovarian serous adenocarcinoma (86.8%) was significantly higher than those of normal ovarian tissues (0) and benign ovarian tumor tissues (36.4%), P < 0.05, and there was no difference between ovarian borderline tumor (70%) and ovarian serous adenocarcinoma, P > 0.05. The expression of BRMS1 in ovarian serous adenocarcinoma (28. 3%) was significantly lower than those in normal ovarian tissues (100%) and benign ovarian tumor tissues (81.8%), P < 0. 05, and there was no difference between ovarian borderline tumor (60%) and ovarian serous adenocarcinoma, P > 0.05. The inverse correlation between the expression of SATB1 and BRMS1 was observed (r = -0.387, P < 0.05). The expression of SATB1 was correlated with surgical stage and lymph node metastasis (P < 0.05), BRMS1 was correlated with surgical stage, lymph node metastasis and tumor size (P < 0.05); SATB1 and BRMS1 had no correlation with the patients whether menopause or not, histopathological grading, ascites (P > 0.05).
Conclusion: SATB1 and BRMS1 might play an important role in the development and lymph node metastasis of ovarian cancer.